AMCS/QUENTIC
5.7.2022 13:02:05 CEST | Business Wire | Press release
The German regulatory authorities have approved the sale of the Quentic GmbH to the AMCS Group. The transaction is hence closed and Quentic will be a part of AMCS as of July 2022.
AMCS, the leading global supplier of integrated software and vehicle technology for the environmental, utility, waste, recycling, and resource industries, and Quentic, one of the leading solution providers of Software as a Service for EHSQ and ESG management, announced the acquisition of Quentic by AMCS on May 12, 2022. As the regulatory authorities have now approved the transaction, the acquisition of the Berlin-based software provider for occupational safety, environmental, sustainability, and quality management took effect on June 30, 2022. "With this step, we open a new chapter in our 15-year company history," explains Markus Becker, CEO of Quentic. "The cooperation will further strengthen Quentic's growth of the past years. We particularly look forward to the professional collaboration and exchange in order to jointly provide the best digital business solutions for a healthier, cleaner and more sustainable future."
Technology portfolio for sustainable business processes
With the addition of Quentic to its portfolio, AMCS expands its offering of promising digital solutions that optimize workflows and have a direct positive impact on the environment. "Regardless of the industry, digitalization is a key enabler on the path to a global and sustainable circular economy," confirms Jimmy Martin CEO of AMCS. "With the variety of solutions in the AMCS portfolio, we aim to put these technologies at the fingertips of our customers. Integrated management of all processes related to occupational safety, environmental, sustainability and quality management, as offered by the Quentic SaaS platform and app, is therefore a valuable addition to our offering," Martin continues.
Becoming a market leader with sustainable growth
Markus Becker, Sebastian Mönnich and Hardy Menzel founded Quentic in 2007. Today, the company employs more than 250 people at 14 locations across Europe. More than 900 companies strengthen their processes in the areas of occupational safety, environmental, sustainability and quality management with Quentic software solutions. Business angels and financial investors supported the company’s growth in several rounds of financing. "We would like to thank our long-term partners One Peak, Morgan Stanley Expansion Capital and High-Tech Gründerfonds for the trustful and valuable cooperation. Together we have successfully put Quentic on the path to becoming the European market leader for EHSQ and ESG-management software and services. Now we are looking forward to continue on this path with AMCS," explains Markus Becker. The Quentic management team will continue to shape the company’s future together with the new owner AMCS.
About AMCS
AMCS is headquartered in Limerick, Ireland with offices in North America, Europe, and Australia employing over 1000 people across 18 countries. AMCS is a global leader of integrated software and vehicle technology for the environmental, recycling, and resource industries and offers optimization solutions to the broader transport and logistics market. AMCS helps over 4,000 customers globally to reduce their operating costs, increase asset utilization, optimize margins, and improve customer service. Their enterprise software and SaaS solutions deliver digital innovation to the emerging circular economy around the world.
About Quentic
Quentic is one of the leading solution providers of Software as a Service (SaaS) for EHSQ and ESG management. The Quentic platform comprises ten individually combinable modules and offers an ideal way for companies to manage Health & Safety, Risks & Audits, Incidents & Observations, Hazardous Chemicals, Control of Work, Legal Compliance, Online Instructions, Processes, Environmental Management and Sustainability.
The company is headquartered in Berlin, Germany, and employs more than 250 people. Branch offices are located in Germany, Austria, Switzerland, Finland, Sweden, Denmark, Belgium, the Netherlands, France, Spain and Italy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005137/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom